Phage- and enzybiotic-coated urinary catheters to prevent recurrent multidrug-resistant bacterial infections.

IF 3.8 2区 医学 Q1 INFECTIOUS DISEASES
Michał Wójcicki, Martyna Cieślik, Katarzyna Haraźna, Agnieszka Sobczak-Kupiec, Andrzej Górski, Ewa Jończyk-Matysiak
{"title":"Phage- and enzybiotic-coated urinary catheters to prevent recurrent multidrug-resistant bacterial infections.","authors":"Michał Wójcicki, Martyna Cieślik, Katarzyna Haraźna, Agnieszka Sobczak-Kupiec, Andrzej Górski, Ewa Jończyk-Matysiak","doi":"10.1080/14787210.2025.2541717","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Catheter-associated urinary tract infections (CAUTIs) are among the most prevalent hospital-acquired infections, posing a serious clinical and economic burden, particularly in the context of rising antibiotic resistance. Biofilm formation on indwelling catheters by multidrug-resistant uropathogens further complicates treatment and prevention, underscoring the urgent need for alternative, non-antibiotic solutions.</p><p><strong>Areas covered: </strong>This article explores the potential of bacteriophage- and enzybiotic-coated urinary catheters as an innovative strategy to prevent recurrent bacterial infections. We review the clinical significance of biofilm formation on the surface of urinary catheters, the role of phages and their lytic enzymes in disrupting biofilms, and the clinical evidence supporting the efficacy of phage therapy. The reference list was compiled through a structured search of peer-reviewed studies and case reports, particularly from recent years, available in the PubMed database.</p><p><strong>Expert opinion: </strong>Phage- and enzybiotic-functionalized catheters represent a promising non-antibiotic approach to CAUTI prevention. These biological agents offer targeted antibacterial activity, disrupt biofilms, and reduce the risk of drug resistance development. Their integration into catheter design may significantly improve infection control, reduce antibiotic use, and align with global antimicrobial stewardship goals. However, clinical standardization and regulatory clarity are crucial for advancing their implementation in routine clinical practice.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-16"},"PeriodicalIF":3.8000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2025.2541717","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Catheter-associated urinary tract infections (CAUTIs) are among the most prevalent hospital-acquired infections, posing a serious clinical and economic burden, particularly in the context of rising antibiotic resistance. Biofilm formation on indwelling catheters by multidrug-resistant uropathogens further complicates treatment and prevention, underscoring the urgent need for alternative, non-antibiotic solutions.

Areas covered: This article explores the potential of bacteriophage- and enzybiotic-coated urinary catheters as an innovative strategy to prevent recurrent bacterial infections. We review the clinical significance of biofilm formation on the surface of urinary catheters, the role of phages and their lytic enzymes in disrupting biofilms, and the clinical evidence supporting the efficacy of phage therapy. The reference list was compiled through a structured search of peer-reviewed studies and case reports, particularly from recent years, available in the PubMed database.

Expert opinion: Phage- and enzybiotic-functionalized catheters represent a promising non-antibiotic approach to CAUTI prevention. These biological agents offer targeted antibacterial activity, disrupt biofilms, and reduce the risk of drug resistance development. Their integration into catheter design may significantly improve infection control, reduce antibiotic use, and align with global antimicrobial stewardship goals. However, clinical standardization and regulatory clarity are crucial for advancing their implementation in routine clinical practice.

噬菌体和酶包膜导尿管预防复发性多药耐药细菌感染。
导读:导尿管相关性尿路感染(CAUTIs)是最普遍的医院获得性感染之一,造成严重的临床和经济负担,特别是在抗生素耐药性上升的背景下。多药耐药尿路病原体在留置导尿管上形成生物膜,进一步复杂化了治疗和预防,强调了迫切需要替代的非抗生素解决方案。涉及领域:本文探讨了噬菌体和酶包被导尿管作为预防复发性细菌感染的创新策略的潜力。本文就导尿管表面生物膜形成的临床意义、噬菌体及其裂解酶在破坏生物膜中的作用以及支持噬菌体治疗效果的临床证据进行综述。参考文献列表是通过对同行评议研究和案例报告的结构化搜索而编制的,特别是近年来的案例报告,可在PubMed数据库中获得。专家意见:噬菌体和酶功能化导管是预防CAUTI的一种很有前途的非抗生素方法。这些生物制剂提供靶向抗菌活性,破坏生物膜,并降低耐药性发展的风险。将其整合到导管设计中可以显著改善感染控制,减少抗生素使用,并与全球抗菌药物管理目标保持一致。然而,临床标准化和监管清晰度对于推进其在常规临床实践中的实施至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信